Titration of cell-associated varicella-zoster virus with the MV9G reporter cell line for antiviral studies

Li, Xiaojie; Li, Xiaoxia; Gong, Wei; Wang, Guanqing; Lu, Z.; Wu, Ningjun; Lian, Chengxiang; Huang, Lan; Inoue, Naoki

doi:10.1016/j.jviromet.2018.06.019

Cited by 2 publications

(1 citation statement)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hence, IFNs could be used to induce a VZV latent phenotype in human neurons or to inhibit VZV reactivation [196]. Concentration of VZV-containing supernatant, use of debris fraction, and generation of reporter cell line are useful techniques to study virus entry and latency, detect virus, and design new antiviral agents [199][200][201]. Numerous efforts have been made to develop adequate animal models of VZV infection but these models remain limited because all aspects of VZV infection, latency and reactivation, understanding VZV pathology will not only remain dif icult but also incomplete without a suitable model [150,184].…”

Section: Animal and Other Experimental Models For Vzvmentioning

confidence: 99%

The beneficial effects of varicella zoster virus

Al-Anazi¹,

Wk²,

Al-Jasser³

2019

J Hematol Clin Res

View full text Add to dashboard Cite

Varicella zoster virus behaves differently from other herpes viruses as it differs from them in many aspects. Recently, there has been growing evidence on the benefi cial effects of the virus in immune compromised hosts and these effects are translated into prolongation of survival. The reported benefi cial effects of the virus include: (1) stimulation of bone marrow activity in patients with hematologic malignancies and bone marrow failure syndromes, (2) antitumor effects in various hematologic malignancies and solid tumors, and (3) association with graft versus host disease which has anticancer effects. Additionally, there are several reports on the safety of the live-attenuated even in severely immune suppressed individuals and on the emerging role of the virus in cancer immunotherapy. In this review, the following aspects of the virus will be thoroughly discussed: (1) new data on the genetic background, pathogenesis, vaccination, and new therapeutic modalities; (2) bone marrow microenvironment and hematopoiesis; (3) cells involved in the pathogenesis of the virus such as: mesenchymal stem cells, dendritic cells, natural killer cells, T-cells and mononuclear cells; (4) cellular proteins such as open reading frames, glycoproteins, promyelocytic leukemia protein, chaperons, and SUMOs; (5) extracellular vesicles, exosomes, and micro-RNAs; and (6) signaling pathways, cytokines, and interferons.

show abstract